Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 6
- Registration Number
- NCT04217317
- Locations
- 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 1
- Registration Number
- NCT04155840
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Yale University
- Registration Number
- NCT04138875
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)
- Conditions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT04127916
- Locations
- 🇰🇷
Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul, Republic of Korea, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, 81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea, Seoul, Korea, Republic of
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 360
- Registration Number
- NCT04115631
- Locations
- 🇺🇸
Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
🇺🇸Providence Newberg Medical Center, Newberg, Oregon, United States
🇺🇸Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04083495
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT04083898
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
FT516 in Subjects With Advanced Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 72
- Registration Number
- NCT04023071
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT04022239
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 510
- Registration Number
- NCT04002297
- Locations
- 🇺🇸
West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.